16 / 35
Page 80
Volume 08
Clinical Pharmacology & Biopharmaceutics
ISSN: 2167-065X
Pharmacology 2019
World Heart Congress 2019
August 19-20, 2019
JOINT EVENT
conferenceseries
.com
August 19-20, 2019 Vienna, Austria
&
7
th
World Heart Congress
24
th
World Congress on
Pharmacology
Right ventricular outflow tract reconstruction
Balram Airan
Mahatma Gandhi Hospital, India
R
ight ventricular outflow tract (RVOT) reconstruction is an integral component of many pediatric cardiac
surgical procedures. Till date the ideal method of performing this remains elusive. This presentation will focus
on the various substitutes available for RVOT reconstruction, their merits and demerits and intermediate and long
term results. Between January 1998 and December 2018, 365 patients underwent right ventricular outflow tract
reconstruction for a variety of indications: Ventricular septal defect with pulmonary atresia (n=231), Tetralogy of
Fallot (n=65) and Tetralogy of Fallot with absent pulmonary valve syndrome (n=69). This excludes patients with
truncus arteriosus in whom valved conduits are the predominant option. The method of RVOT reconstruction was
pulmonary homograft (n=137), aortic homograft (n=62), direct anastomosis of the main pulmonary artery to the
RVOT (n=32) in patients with ventricular septal defect with pulmonary atresia. For the other two indications, the
methods adopted were monocusp pulmonary valve reconstruction with autologous pericardium (n=59), bicuspid
pulmonary valve using PTFE membrane (n=49) and RVOT reconstruction using a homograft monocusp (n=26). In
patients with homograft implantation there were no significant early gradients and the valves were competent in all.
In patients with pericardial monocusps there was mild insufficiency in immediate follow-up, moderate at three years
of follow-up in 16 and severe in 35 patients at 6 to 13 years of follow-up. In patients with PTFE valve reconstruction
that was adopted recently, freedom from significant stenosis or regurgitation was 87% at a median follow-up four
years. In patients with homograft monocusp preconstruction, freedom from the latter was 74% at a median follow-
up of six years. There were 35 re-operations for change of the conduit after a median follow-up ranging 9 to 13 years.
We conclude that the methods of RVOT reconstruction need to be tailored to the individual patient anatomy and
using a variety of these techniques, satisfactory results may be obtained.
Clin Pharmacol Biopharm, Volume 08